RESUMEN
BACKGROUND: Dentin hypersensitivity, often occurring after dental treatments or from erosive lesions, is a prevalent patient complaint. This study introduces a paste combining 8% L-arginine, calcium carbonate, and potassium nitrate to evaluate its impact on dentinal tubules occlusion, dentin permeability, and tooth sensitivity. METHODS: Dentin surfaces from 24 third molars (thickness: 2 mm) were divided into two groups of 12. One received the experimental paste, while the other received a placebo without desensitizer. Permeability and sealing ability were assessed through scanning electron microscopy (SEM) and dentin permeability measurement. The pastes' effects on hypersensitivity were then examined in a triple-blind, randomized parallel-armed clinical trial with 16 eligible patients. Sensitivity to cold, touch, and spontaneous stimuli was recorded using the VAS scale at various intervals post-treatment. Statistical analysis was conducted using Shapiro-Wilk, Mann-Whitney U, Friedman, and Wilcoxon tests (α = 0.05). RESULTS: The permeability test demonstrated a significant reduction in dentin permeability in the experimental group (P = 0.002) compared to the control (P = 0.178). SEM images revealed most dentinal tubules in the intervention samples to be occluded. Clinically, both groups showed a significant decrease in the three types of evaluated sensitivity throughout the study. However, no significant difference in sensitivities between the two groups was observed, with the exception of cold sensitivity at three months post-treatment (P = 0.054). CONCLUSION: The innovative desensitizing paste featuring 8% L-arginine, calcium carbonate, and potassium nitrate effectively occluded dentinal tubules and reduced dentin permeability. It mitigated immediate and prolonged dentin hypersensitivity to various stimuli, supporting its potential role in managing dentin hypersensitivity. TRIAL REGISTRATION: http://irct.ir : IRCT20220829055822N1, September 9th, 2022.
Asunto(s)
Arginina , Carbonato de Calcio , Desensibilizantes Dentinarios , Sensibilidad de la Dentina , Microscopía Electrónica de Rastreo , Nitratos , Compuestos de Potasio , Humanos , Sensibilidad de la Dentina/tratamiento farmacológico , Arginina/uso terapéutico , Carbonato de Calcio/uso terapéutico , Nitratos/uso terapéutico , Masculino , Femenino , Compuestos de Potasio/uso terapéutico , Desensibilizantes Dentinarios/uso terapéutico , Adulto , Permeabilidad de la Dentina/efectos de los fármacos , Dentina/efectos de los fármacos , Pastas de Dientes/uso terapéutico , Adulto Joven , Persona de Mediana EdadRESUMEN
BACKGROUND AND AIMS: Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective but this observation is yet to be translated clinically. In this study, the efficacy of inorganic nitrate in the prevention of CIN in high-risk patients presenting with acute coronary syndromes (ACS) is reported. METHODS: NITRATE-CIN is a double-blind, randomized, single-centre, placebo-controlled trial assessing efficacy of inorganic nitrate in CIN prevention in at-risk patients presenting with ACS. Patients were randomized 1:1 to once daily potassium nitrate (12 mmol) or placebo (potassium chloride) capsules for 5 days. The primary endpoint was CIN (KDIGO criteria). Secondary outcomes included kidney function [estimated glomerular filtration rate (eGFR)] at 3 months, rates of procedural myocardial infarction, and major adverse cardiac events (MACE) at 12 months. This study is registered with ClinicalTrials.gov: NCT03627130. RESULTS: Over 3 years, 640 patients were randomized with a median follow-up of 1.0 years, 319 received inorganic nitrate with 321 received placebo. The mean age of trial participants was 71.0 years, with 73.3% male and 75.2% Caucasian; 45.9% had diabetes, 56.0% had chronic kidney disease (eGFR <60 mL/min) and the mean Mehran score of the population was 10. Inorganic nitrate treatment significantly reduced CIN rates (9.1%) vs. placebo (30.5%, P < .001). This difference persisted after adjustment for baseline creatinine and diabetes status (odds ratio 0.21, 95% confidence interval 0.13-0.34). Secondary outcomes were improved with inorganic nitrate, with lower rates of procedural myocardial infarction (2.7% vs. 12.5%, P = .003), improved 3-month renal function (between-group change in eGFR 5.17, 95% CI 2.94-7.39) and reduced 1-year MACE (9.1% vs. 18.1%, P = .001) vs. placebo. CONCLUSIONS: In patients at risk of renal injury undergoing coronary angiography for ACS, a short (5 day) course of once-daily inorganic nitrate reduced CIN, improved kidney outcomes at 3 months, and MACE events at 1 year compared to placebo.
Asunto(s)
Síndrome Coronario Agudo , Lesión Renal Aguda , Medios de Contraste , Angiografía Coronaria , Nitratos , Humanos , Angiografía Coronaria/efectos adversos , Angiografía Coronaria/métodos , Medios de Contraste/efectos adversos , Masculino , Femenino , Método Doble Ciego , Nitratos/administración & dosificación , Nitratos/uso terapéutico , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/prevención & control , Anciano , Persona de Mediana Edad , Tasa de Filtración Glomerular/efectos de los fármacos , Compuestos de Potasio/administración & dosificación , Compuestos de Potasio/uso terapéuticoRESUMEN
Aim: Hypersensitivity is the most common clinical problem which is encountered by most of dental patients undergoing a vital tooth preparation for a fixed crown prosthesis. The aim of this study is to evaluate the effect of silver diamine fluoride, potassium nitrate, and glutaraldehyde in reducing dentinal hypersensitivity following vital tooth preparation. Settings and Design: This study is a randomized control trial performed on 119 teeth of 68 patients who are in need of fixed prosthesis treatment. Materials and Methods: After a thorough clinical examination, patients were allocated into any of the randomly assigned four groups (Control, silver diamine fluoride, potassium nitrate, and glutaraldehyde) and the level of hypersensitivity was measured by blasting air on the surface of tooth at five different intervals (before preparation, after preparation, after application of desensitizers, before cementation and after a follow up period of about 30 days) and is graded using Schiff 's cumulative hypersensitivity index. Statistical Analysis Used: Kruskal wallis test is used to compare the rate of sensitivity between the 4 groups. Friedman and Wilcoxon test is used to compare the rate of sensitivity at 5 different intervals. Results: All the desensitizers used in this study reduced the level of hypersensitivity. Among which, silver diamine fluoride was found to be more effective after application, before cementation, and after a follow up period of about 30 days followed by GLUMA and potassium nitrate. Conclusion: The results of this study suggest that silver diamine fluoride was found to be more effective after application, before cementation of the definitive prosthesis and after a follow up period of 30 days.
Asunto(s)
Sensibilidad de la Dentina , Humanos , Sensibilidad de la Dentina/prevención & control , Sensibilidad de la Dentina/diagnóstico , Sensibilidad de la Dentina/tratamiento farmacológico , Compuestos de Potasio/uso terapéutico , Preparación del DienteRESUMEN
OBJECTIVE: The aims of this study were to evaluate whether the use of a dentifrice containing 5% potassium nitrate (KNO3 ) prior to and during in-office dental bleaching reduces bleaching-induced tooth sensitivity and affects bleaching efficiency. MATERIALS AND METHODS: Thirty-eight individuals were randomly distributed into two groups (n = 19). The experimental group performed toothbrushing using a dentifrice containing 5% KNO3 , one week before treatment and before the first and second bleaching sessions. In the control group, a placebo dentifrice without KNO3 was applied as described for the first group. Tooth sensitivity was recorded on visual analog scales (VAS) and numeric rating scales (NRS) immediately and up to 48 h after bleaching sessions. Color change at different time intervals, was evaluated with shade guide units (∆SGU) and a digital spectrophotometer (∆E CIELab 1976 and CIEDE2000) at baseline and 7, 15, and 30 days post-bleaching. Mann-Whitney test and t-test were used to evaluate TS intensity for NRS and VAS scales, respectively, and T-test was used for color difference evaluation. RESULTS: No significant difference in tooth sensitivity's absolute risk and intensity were observed between tested groups in any evaluated treatment time for NRS (p = 0.91) or VAS scales (p = 0.48). T-test showed no significant difference in both ∆E and ∆SGU tooth color among the experimental and control groups during the different evaluation times (p = 0.27). CONCLUSION: The use of a dentifrice containing 5% KNO3 does not prevent post-operatory tooth sensitivity but allows the same whitening efficiency as a regular dentifrice. CLINICAL SIGNIFICANCE: The use of a dentifrice-containing KNO3 did not prevent bleaching-induced tooth sensitivity when high-concentrated hydrogen peroxide was used for in-office bleaching.
Asunto(s)
Dentífricos , Sensibilidad de la Dentina , Blanqueadores Dentales , Blanqueamiento de Dientes , Dentífricos/uso terapéutico , Sensibilidad de la Dentina/tratamiento farmacológico , Sensibilidad de la Dentina/prevención & control , Humanos , Peróxido de Hidrógeno/efectos adversos , Nitratos , Compuestos de Potasio/uso terapéutico , Blanqueamiento de Dientes/efectos adversos , Blanqueadores Dentales/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND: Bromide is a halide ion of the element bromine usually administered in the form of potassium salt as monotherapy or add-on treatment in epileptic dogs. It is excreted unchanged in the urine and undergoes tubular reabsorption in competition with chloride. Thus, dietary chloride content affects serum bromide concentrations. This is the first published clinical report of bromide toxicosis secondary to a dietary modification of chloride content in an epileptic dog treated with potassium bromide. CASE PRESENTATION: A 3-year-old 55-kg neutered male Tibetan Mastiff was evaluated because of a 1-month history of progressive signs including ataxia, lethargy and behaviour changes. The dog was successfully treated for idiopathic epilepsy since the age of 1-year-old with phenobarbital and potassium bromide. Two months prior to presentation, the owners decided to change the dog's diet without veterinary advice. Physical examination was unremarkable. A 12-kg weight gain was recorded since last follow-up (8 months). Neurological examination revealed severe symmetric 4-limbs ataxia with altered vigilance and intermittent episodes of hyperactivity and aggressive behaviour without significant abnormality of cranial nerves. Serum bromide concentration was high and increased by 103 % since last follow-up. Nutritional evaluation revealed a 53 % decrease of chloride content in the diet before and after dietary transition. Bromide toxicosis was suspected, due to bromide reduced clearance secondary to the decreased dietary chloride content. Potassium bromide treatment was lowered by 15 % without further dietary changes. Neurologic signs progressively improved over the next month, without any seizure. After two months, the serum bromide concentration lowered to the same level measured before dietary modification. After four months, neurological examination was unremarkable. CONCLUSIONS: Dietary chloride content can directly influence serum bromide concentrations, therefore affecting seizure control or contributing to unexpected adverse effects. In the present case, a reduction in chloride intake markedly increased serum bromide concentrations causing bromism. Dietary changes should be avoided in dogs treated with potassium bromide to maintain stable serum bromide levels.
Asunto(s)
Bromuros/efectos adversos , Bromuros/uso terapéutico , Cloruros/administración & dosificación , Dieta/veterinaria , Enfermedades de los Perros/inducido químicamente , Epilepsia/veterinaria , Compuestos de Potasio/efectos adversos , Compuestos de Potasio/uso terapéutico , Animales , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Perros , Epilepsia/tratamiento farmacológico , MasculinoRESUMEN
Seizure threshold-2 (SZT2) gene variants have been associated with a decrease in seizure threshold resulting in variable phenotypic expressions ranging from mild-moderate intellectual disabilities without seizures, to an early-onset epileptic encephalopathy with severe cognitive impairment. In addition, hypotonia and distinctive facial dysmorphism, including a high forehead and to a lesser extent ptosis and down-slanting palpebral fissures, were present in the majority. We herein report a novel SZT2 variant in one of two siblings both diagnosed with epilepsy of infancy with migrating focal seizures (EIMFS). This report is the fourth to document a possible familial case in EIMFS, a condition that was not previously associated with SZT2 variant. This report expands the phenotypic expression of SZT2, corroborates the importance of genetic counseling in some cases of EIMFS, and highlights the efficacy of potassium bromide in controlling the seizures associated with this condition.
Asunto(s)
Síndromes Epilépticos/genética , Proteínas del Tejido Nervioso/genética , Convulsiones/genética , Espasmos Infantiles/genética , Bromuros/uso terapéutico , Consanguinidad , Electroencefalografía , Resultado Fatal , Femenino , Humanos , Lactante , Recién Nacido , Fenotipo , Compuestos de Potasio/uso terapéutico , Convulsiones/tratamiento farmacológico , GemelosRESUMEN
BACKGROUND: A new prolonged-release formulation of potassium citrate and potassium bicarbonate, ADV7103, has been shown to improve metabolic control, palatability, and gastrointestinal safety in patients with distal renal tubular acidosis (dRTA) when compared to standard of care (SoC) treatments. The present work evaluates safety and efficacy of ADV7103 during 24 months. METHODS: Thirty pediatric and adult patients were included in an open-label extension study after a phase II/III trial. Safety and tolerability were assessed. Plasma bicarbonate and potassium levels, as well as urine parameters, were evaluated over time. Acceptability, adherence, and quality of life were also assessed. The evolution of clinical consequences of dRTA in the cohort was explored. RESULTS: There were 104 adverse events (AEs) reported, but only 9 gastrointestinal events observed in five patients (17%) were considered to be related to ADV7103 treatment. There were no AEs leading to treatment discontinuation. Plasma bicarbonate and potassium levels were in the normal ranges at the different visits, respectively, in 69-86% and 83-93% of patients. Overall adherence rates were ≥ 75% throughout the whole study in 79% patients. An average improvement of quality of life of 89% was reported at 24 months of study. CONCLUSIONS: Common AEs concerned metabolism and gastrointestinal disorders; the former being related to the disease. Less than half of the gastrointestinal AEs were related to ADV7103 treatment and they were mostly mild in severity. Metabolic parameters were maintained in the normal ranges in most patients. Patient satisfaction was high and adherence to treatment was good and remained stable. TRIAL REGISTRATION NUMBER: Registered as EudraCT 2013-003828-36 on the 3rd of September 2013.
Asunto(s)
Acidosis Tubular Renal , Bicarbonatos , Citrato de Potasio , Compuestos de Potasio , Acidosis Tubular Renal/tratamiento farmacológico , Adulto , Bicarbonatos/efectos adversos , Bicarbonatos/uso terapéutico , Niño , Humanos , Potasio , Citrato de Potasio/efectos adversos , Citrato de Potasio/uso terapéutico , Compuestos de Potasio/efectos adversos , Compuestos de Potasio/uso terapéutico , Calidad de VidaRESUMEN
<b>Background and Objective:</b> Protocols commonly used in plant DNA extraction were known to be highly time-consuming and harmful due to the application of some hazardous reagents. Therefore, it was not applicable for such laboratories with limited resources as well as for high-throughput analysis. This study was aimed to develop a rapid yet less hazardous DNA extraction protocol for a plant using potassium phosphate buffer. <b>Materials and Methods:</b> Genomic DNA of chili pepper (<i>Capsicum annuum</i>) was extracted using potassium phosphate buffer and its efficacy was compared to three widely known protocols (CTAB-based, mini preparation and commercial kit). The extracted DNA from those four methods was evaluated based on its quality, quantity, practicality and cost per reaction. <b>Results:</b> Genomic DNA resulted from potassium phosphate buffer-based protocol exhibited comparable quality with adequate concentration for further downstream analysis. Results of PCR and sequencing were also emphasized the amplifiable DNA quality from this developed protocol. Compared to those commonly used protocols, potassium phosphate buffer consisted of 5 main working steps only, thus providing a simple yet rapid plant DNA extraction protocol. Since this protocol used ethanol only, it also offered a less hazardous and low-cost protocol that applicable for those resource-limited laboratories. <b>Conclusion:</b> This developed protocol provided a promising alternative of plant DNA extraction that might be applicable for both large scale analysis and any laboratory type. Further investigation was needed to evaluate its efficacy in extracting genomic DNA from various plants with different morphological characteristic.
Asunto(s)
Tampones (Química) , ADN de Plantas/análisis , Fosfatos/metabolismo , Compuestos de Potasio/metabolismo , Análisis de Secuencia de ADN/métodos , Fosfatos/uso terapéutico , Reacción en Cadena de la Polimerasa/métodos , Compuestos de Potasio/uso terapéutico , Análisis de Secuencia de ADN/instrumentaciónRESUMEN
Sjogren syndrome (SS) is a systemic autoimmune disorder with predominant exocrine gland involvement leading to sicca symptoms. Among extraglandular manifestations, renal disease is the most common. Tubular interstitial nephritis and renal tubular acidosis (RTA) are the common presentations. Mild hypokalemia associated with distal RTA is common in SS, however, severe hypokalemia causing paralysis is unusual. We report the case of a 26-year-old female who presented with hypokalemic paralysis. On evaluation, distal RTA was diagnosed. Further evaluation showed positive SS-a/SS-b antibodies in high titer, which confirms the diagnosis of primary SS. Our report illustrates that SS is a rare but important cause of hypokalemic paralysis.
Résumé syndrome de Sjogren (SS) est une maladie auto-immune systémique avec une atteinte prédominante des glandes exocrines entraînant des symptômes de sicca. Parmi manifestations extraglandulaires, la maladie rénale est la plus courante. La néphrite interstitielle tubulaire et l'acidose tubulaire rénale (RTA) sont les présentations. Une hypokaliémie légère associée à un RTA distal est courante dans les SS, cependant, une hypokaliémie sévère provoquant une paralysie est inhabituelle. Nous rapportons le cas d'une femme de 26 ans qui présentait une paralysie hypokaliémique. À l'évaluation, un RTA distal a été diagnostiqué. Plus loin l'évaluation a montré des anticorps SS-a / SS-b positifs à titre élevé, ce qui confirme le diagnostic de SS primaire. Notre rapport montre que SS est un cause rare mais importante de paralysie hypokaliémique.
Asunto(s)
Acidosis Tubular Renal/complicaciones , Hipopotasemia/diagnóstico , Parálisis/etiología , Síndrome de Sjögren/diagnóstico , Administración Intravenosa , Administración Oral , Adulto , Anticuerpos Antinucleares/sangre , Bicarbonatos/administración & dosificación , Bicarbonatos/uso terapéutico , Femenino , Humanos , Hipopotasemia/tratamiento farmacológico , Parálisis Periódica Hiperpotasémica , Cloruro de Potasio/administración & dosificación , Cloruro de Potasio/uso terapéutico , Citrato de Potasio/administración & dosificación , Citrato de Potasio/uso terapéutico , Compuestos de Potasio/administración & dosificación , Compuestos de Potasio/uso terapéutico , Síndrome de Sjögren/etiología , Resultado del TratamientoAsunto(s)
Anticonvulsivantes/efectos adversos , Bromuros/efectos adversos , Dermatitis Exfoliativa/diagnóstico , Erupciones por Medicamentos , Compuestos de Potasio/efectos adversos , Adulto , Anticonvulsivantes/uso terapéutico , Bromuros/uso terapéutico , Dermatitis Exfoliativa/inducido químicamente , Dermatitis Exfoliativa/complicaciones , Epilepsia/tratamiento farmacológico , Femenino , Humanos , Compuestos de Potasio/uso terapéuticoRESUMEN
Background: Lasers have been used for verruca treatment in recent years with successful results in some types. In addition, peeling processes have been used to enhance penetration in some studies.Objectives: This study aimed to evaluate combined treatment with LP Nd:YAG laser and KoH for the treatment of recalcitrant wart.Methods: This study included 132 lesions from 38 patients. Long-pulsed (LP) Nd:YAG laser was applied to 66 lesions with daily 10% KOH application at night, and the remaining 66 lesions underwent LP Nd:YAG laser therapy only.Results: Both groups showed statistically significant regressions in the size of the lesions at the end of the fifth session compared with those present at the onset of therapy (p < .05). Also, complete clearance of the lesions was noticed after 2.2 sessions in the combined therapy group, and after 3.1 sessions in the LP Nd:YAG laser group (p < .05).Conclusions: Although the difference in clearance rate between the combined therapy group and the LP Nd:YAG laser group could not be detected after the fifth session, adding KOH to LP Nd:YAG laser can decrease the number of treatment sessions to a large extent.
Asunto(s)
Hidróxidos/uso terapéutico , Láseres de Estado Sólido , Compuestos de Potasio/uso terapéutico , Verrugas/terapia , Adolescente , Adulto , Niño , Terapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neodimio/química , Estudios Prospectivos , Resultado del Tratamiento , Adulto JovenAsunto(s)
Anticonvulsivantes/efectos adversos , Bromuros/efectos adversos , Erupciones por Medicamentos/diagnóstico , Epilepsia Refractaria/tratamiento farmacológico , Compuestos de Potasio/efectos adversos , Anticonvulsivantes/uso terapéutico , Bromuros/uso terapéutico , Erupciones por Medicamentos/etiología , Humanos , Lactante , Masculino , Compuestos de Potasio/uso terapéuticoRESUMEN
KCNT1 encodes a sodium-activated potassium channel highly expressed in the brain, regulating hyperpolarization following repetitive firing. Mutations in KCNT1 were originally implicated in autosomal-dominant nocturnal frontal lobe epilepsy and epilepsy of infancy with migrating focal seizures. It is now known that there is variability in phenotypic expression and incomplete penetrance. We describe 2 patients with KCNT1-related epilepsy, one with epilepsy of infancy with migrating focal seizures and one with multifocal epilepsy. As most patients with KCNT1 variants have treatment-resistant epilepsy, drugs that specifically target the KCNT1 channel have been of great interest. Quinidine, a broad-spectrum potassium channel blocker, has shown promise; however, clinical trial results have been variable. Our patient with epilepsy of infancy with migrating focal seizures did not respond to a trial of quinidine at 6 weeks of age-one of the earliest reported quinidine trials in the literature for KCNT1-related epilepsy. This indicates that timing of treatment and response may not be related. Both patients responded to high-dose phenobarbital. The patient with epilepsy of infancy with migrating focal seizures also had a significant reduction in seizures with potassium bromide (KBr). Our data suggest that alternative therapies to quinidine should be considered as a therapeutic option for patients with KCNT1-related epilepsy. Although improved seizure control led to parent-reported improvements in neurodevelopment, it is unknown if phenobarbital and KBr impact the overall developmental trajectory of patients with KCNT1-related epilepsy. Further multicenter longitudinal studies are required.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Bromuros/uso terapéutico , Epilepsia/tratamiento farmacológico , Mutación , Proteínas del Tejido Nervioso/genética , Fenobarbital/uso terapéutico , Canales de potasio activados por Sodio/genética , Compuestos de Potasio/uso terapéutico , Preescolar , Quimioterapia Combinada , Electroencefalografía , Epilepsia/genética , Resultado Fatal , Humanos , Lactante , Masculino , Resultado del TratamientoRESUMEN
Aims: To assess the use of potassium bromide (KBr) as a therapeutic intervention for perennial ryegrass toxicosis (PRGT) in lambs fed ryegrass seed containing lolitrem B. Methods: Male lambs aged 10-12 months (n = 43) were assigned to receive ryegrass seed containing lolitrem B, at a dose of 0.16â mg/kg/day (Groups 2, 3 and 4), or lucerne chaff and molasses (Groups 1 and 5). Lambs in Groups 2 and 3 were observed for clinical signs and gait changes until defined signs of PGRT were observed, when they were transferred, with lambs in Group 1, to the Testing phase of the trial. Lambs in Group 3 were then treated with a single oral dose of 300â mg/kg bromide. Lambs in Groups 4 and 5 received KBr daily from the start of the trial (540â mg/kg bromide over 3 days then 20â mg/kg daily) and were transferred to the Testing phase after 18 days. Clinical examination and gait assessment, and surface electromyography of the triceps muscle, measuring root-mean-square (RMS) voltages, were carried out on Days 0, 1 and 2 of the Testing phase followed by necropsy, histopathology, measurement of concentrations of bromide in serum and CSF and faecal cortisol metabolites (FCM). Results: In Group 3 lambs, mean composite gait scores decreased between Testing phase Day 0 and Days 1 and 2 (p < 0.001), but increased in lambs in Group 2 between Day 0 and Day 2 (p = 0.015). Scores for lambs in Group 3 on Day 2 were lower than for lambs in Group 2 (p < 0.001). Mean RMS voltages on Day 2 were higher in lambs in Group 2 than Group 3 (p = 0.045). Mean concentrations of bromide in serum were >800â µg/mL in lambs in Groups 3 and 4 on Day 2. Concentrations of FCM were higher in lambs from Group 2 than in Groups 1 or 5, but were similar in Groups 2, 3 and 4. Histopathological findings in the cerebellum of lambs from Groups 2, 3 and 4 were similar, showing pyknosis of neurons within the granular layer of the cerebellum and Purkinje neuron proximal axonal spheroid formation. Conclusions and clinical relevance: A single oral dose of 300â mg/kg bromide in lambs with neurological signs of PRGT resulted in reduced composite gait scores and reduced RMS voltages, indicating a significant improvement in clinical signs of ataxia, movement disorder and muscle tremor associated with the neurotoxic effects of lolitrem B.
Asunto(s)
Alimentación Animal , Ataxia/veterinaria , Bromuros/uso terapéutico , Compuestos de Potasio/uso terapéutico , Enfermedades de las Ovejas/prevención & control , Temblor/veterinaria , Alimentación Animal/efectos adversos , Alimentación Animal/análisis , Alimentación Animal/microbiología , Animales , Animales Recién Nacidos , Ataxia/prevención & control , Ergotamina/efectos adversos , Ergotamina/análisis , Alcaloides Indólicos , Lolium/microbiología , Micotoxinas/administración & dosificación , Micotoxinas/efectos adversos , Ovinos , Enfermedades de las Ovejas/inducido químicamente , Temblor/inducido químicamente , Temblor/prevención & controlRESUMEN
OBJECTIVE: We evaluated potassium bromide's (KBr's) efficacy and tolerability for pediatric refractory epilepsy. METHODS: We retrospectively reviewed the records of 42 patients treated with KBr in our hospital between 2008 and 2016 (age: 4 months to 19 years; mean: 6.2 years). Thirteen of them had 2 seizure types. The treatment durations ranged from 1 month to 6 years (mean: 15.0 months). RESULTS: KBr had an excellent effect (seizure-free status) in 3 patients (7.1%), a moderate effect (>50% reduction in seizure frequency from the pretreatment baseline) in 21 patients (50.0%), and no effect (<50% reduction in seizure frequency from the pretreatment baseline) in 18 patients (42.9%). The effective daily doses ranged from 20 to 80 mg/kg (mean: 50.0 mg/kg). KBr was effective in 59.1% patients with generalized epilepsy (n = 22), 55.6% patients with focal epilepsy (n = 18), and both patients with Dravet syndrome. An excellent or moderate effect was found in 72.2% patients with tonic seizures (n = 18), 66.6% patients with generalized tonic-clonic seizures (n = 6), 75.0% patients with secondary generalized seizures (n = 4), 46.2% patients with focal seizures (n = 13), and 20% patients with infantile spasms (n = 10) but no patients with myoclonic seizures (n = 2). Adverse effects including drowsiness, excitement, and rashes were reported in 13 patients (31.0%). CONCLUSIONS: These findings suggest that KBr is particularly effective for tonic seizures, generalized tonic-clonic seizures, and secondary generalized seizures. Although the adverse effects need further attention, KBr should be considered for pediatric refractory epilepsy.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Bromuros/uso terapéutico , Epilepsia Refractaria/tratamiento farmacológico , Compuestos de Potasio/uso terapéutico , Adolescente , Anticonvulsivantes/efectos adversos , Bromuros/efectos adversos , Niño , Preescolar , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Generalizada/tratamiento farmacológico , Femenino , Humanos , Lactante , Masculino , Compuestos de Potasio/efectos adversos , Estudios Retrospectivos , Convulsiones/tratamiento farmacológico , Resultado del Tratamiento , Adulto JovenRESUMEN
Introduction: Our objective was to assess efficacy, safety and tolerance of topical potassium hydroxide (KOH) 10% for treating Molluscum contagiosum (MC) in children. Material and methods: Randomized, double-blind, placebo-controlled clinical trial including all children 2-16 years with MC infection attending pediatrician primary healthcare visits. The treatment was KOH 10% gel applied once daily up to clearing (maximum 30 days). Results: KOH 10% showed superior efficacy to placebo (55.3% vs 16.3%, p < .001). Time until clearing was inferior with KOH 10% (p = .001). MC lesions were reduced with KOH 10%, which also showed higher efficacy when the instructions of use of the device were modified. KOH 10% patients presented more adverse events (AE) than placebo patients (72.3% vs 31.8%, p < .001). Most patients (91.5%) completely recovered. There were no differences in frequency of AE before and after the change of instructions, intolerance was more frequently reported by parents with new instructions. Conclusions: KOH 10% was superior to placebo in the main efficacy outcome and most secondary efficacy outcomes. KOH 10% patients had more AE and intolerance symptoms than placebo, although there were no severe AE and most patients recovered. KOH 10% is an effective and safe topical treatment for MC infection in children.
Asunto(s)
Hidróxidos/uso terapéutico , Molusco Contagioso/tratamiento farmacológico , Compuestos de Potasio/uso terapéutico , Administración Tópica , Adolescente , Niño , Preescolar , Método Doble Ciego , Femenino , Humanos , Hidróxidos/efectos adversos , Hidróxidos/química , Masculino , Efecto Placebo , Compuestos de Potasio/efectos adversos , Compuestos de Potasio/química , Soluciones/química , Resultado del TratamientoRESUMEN
BACKGROUND: Cardioplegia is an integral part of myocardial protection. The superiority of blood cardioplegia in adult patients has been reported. However, this is yet to be studied in cyanotic pediatric patients. METHODS: A randomized open-label trial was conducted in 70 patients with tetralogy of Fallot. They were divided into two groups: 35 patients had crystalloid cardioplegia (controls), and 35 had blood cardioplegia. Lactate and coronary oxygen extraction in arterial blood and the coronary sinus were measured immediately after cessation of cardiopulmonary bypass, 15 and 30 min later. Postoperative mortality, major adverse cardiac events, mechanical ventilation time, inotrope administration, arrhythmias, right ventricular function, intensive care unit and hospital length of stay were observed. RESULTS: There were no significant differences in clinical outcomes or lactate levels. There was a significant difference in coronary oxygen extraction immediately and 15 min after cessation of cardiopulmonary bypass ( p = 0.038, p = 0.015). CONCLUSION: Blood cardioplegia gave a better postoperative oxygen extraction value but there were no differences in myocardial damage or clinical outcome between the two groups.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Soluciones Cardiopléjicas/uso terapéutico , Puente Cardiopulmonar , Paro Cardíaco Inducido/métodos , Compuestos de Potasio/uso terapéutico , Tetralogía de Fallot/cirugía , Adolescente , Adulto , Biomarcadores/sangre , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Soluciones Cardiopléjicas/efectos adversos , Puente Cardiopulmonar/efectos adversos , Niño , Preescolar , Cianosis/sangre , Cianosis/etiología , Femenino , Paro Cardíaco Inducido/efectos adversos , Humanos , Indonesia , Lactante , Recién Nacido , Ácido Láctico/sangre , Masculino , Oxígeno/sangre , Complicaciones Posoperatorias/etiología , Compuestos de Potasio/efectos adversos , Factores de Riesgo , Tetralogía de Fallot/sangre , Tetralogía de Fallot/complicaciones , Tetralogía de Fallot/diagnóstico por imagen , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVES: To evaluate the effect of photobiomodulation with low-level laser therapy (PBM-LLLT) combined with 5% potassium nitrate (KNO3) on controlling tooth sensitivity (TS) after in-office tooth bleaching. MATERIALS AND METHODS: Fifty volunteers were selected based on the inclusion and exclusion criteria and were randomly allocated into four groups: G1 (control): placebo gel application, 35% hydrogen peroxide bleaching (HP35) and mock PBM-LLLT without light emission; G2: placebo gel application, bleaching with HP35 and PBM-LLLT; G3: application of KNO3, bleaching with HP35 and mock PBM-LLLT; and G4: application of KNO3, bleaching with HP35 and PBM-LLLT. A pain assessment questionnaire was used to evaluate TS during the 21 days of treatment. The Friedman test was used for intragroup analysis, and the Wilcoxon and Mann-Whitney tests were used for intergroup comparisons. RESULTS: The intragroup evaluation showed significant differences among the evaluation times in all groups (p ≤ 0.05). The highest pain sensitivity levels were recorded on the 1st, 8th, and 15th days. In G1, TS manifested for up to 3 days after each bleaching session, while G2, G3, and G4 presented TS only on the days of the bleaching sessions. Intergroup analysis showed that TS manifestation differed significantly between G1 and the other groups (p ≤ 0.05) but did not differ significantly among G2, G3, and G4 (p ≥ 0.05). CONCLUSION: PBM-LLLT and KNO3 are effective at reducing pain sensitivity after tooth bleaching, but no synergistic effect between these treatments was observed for the different evaluation periods. CLINICAL RELEVANCE: The effect of PBM-LLLT combined with KNO3 on post-bleaching tooth sensitivity is similar to their individual use alone.
Asunto(s)
Sensibilidad de la Dentina/terapia , Terapia por Luz de Baja Intensidad , Nitratos/uso terapéutico , Compuestos de Potasio/uso terapéutico , Blanqueamiento de Dientes/efectos adversos , Adulto , Sensibilidad de la Dentina/prevención & control , Método Doble Ciego , Femenino , Humanos , Peróxido de Hidrógeno/administración & dosificación , Masculino , Blanqueadores Dentales/administración & dosificación , Resultado del Tratamiento , Adulto JovenRESUMEN
Potassium bicarbonate was administrated to an already alkaline diet in seven male subjects during a 21-day bed rest study and was able to decrease bed rest induced increased calcium excretion but failed to prevent bed rest-induced bone resorption. INTRODUCTION: Supplementation with alkali salts appears to positively influence calcium and bone metabolism and, thus, could be a countermeasure for population groups with an increased risk for bone loss. However, the extent to which alkalization counteracts acid-induced bone resorption or whether it merely has a calcium and bone maintenance effect is still not completely understood. In the present study, we hypothesized that additional alkalization to an already alkaline diet can further counteract bed rest-induced bone loss. METHODS: Seven healthy male subjects completed two parts of a crossover designed 21-day bed rest study: bed rest only (control) and bed rest supplemented with 90 mmol potassium bicarbonate (KHCO3) daily. RESULTS: KHCO3supplementation during bed rest resulted in a more alkaline status compared to the control intervention, demonstrated by the increase in pH and buffer capacity level (pH p = 0.023, HCO3p = 0.02, ABE p = 0.03). Urinary calcium excretion was decreased during KHCO3 supplementation (control 6.05 ± 2.74 mmol/24 h; KHCO3 4.87 ± 2.21 mmol/24 h, p = 0.03); whereas, bone formation was not affected by additional alkalization (bAP p = 0.58; PINP p = 0.60). Bone resorption marker UCTX tended to be lower during alkaline supplementation (UCTX p = 0.16). CONCLUSIONS: The more alkaline acid-base status, achieved by KHCO3 supplementation, reduced renal calcium excretion during bed rest, but was not able to prevent immobilization-induced bone resorption. However, advantages of alkaline salts on bone metabolism may occur under acidic metabolic conditions or with respect to the positive effect of reduced calcium excretion within a longer time frame. TRIAL REGISTRATION: Trial number: NCT01509456.
Asunto(s)
Reposo en Cama/efectos adversos , Bicarbonatos/uso terapéutico , Resorción Ósea/prevención & control , Suplementos Dietéticos , Compuestos de Potasio/uso terapéutico , Adulto , Bicarbonatos/farmacología , Biomarcadores/metabolismo , Resorción Ósea/etiología , Resorción Ósea/metabolismo , Calcio/orina , Estudios Cruzados , Humanos , Concentración de Iones de Hidrógeno/efectos de los fármacos , Inmovilización/efectos adversos , Inmovilización/fisiología , Masculino , Osteogénesis/efectos de los fármacos , Compuestos de Potasio/farmacología , Soporte de Peso/fisiología , Adulto JovenRESUMEN
OBJECTIVE: This systematic review and Meta-analysis aimed to compare the efficacy of calcium sodium phos-phosilicate (CSPS) and potassium nitrate as desensitizing agents for the treatment of dentin hypersensitivity (DH). METHODS: A thorough search in The Cochrane Library, PubMed, Embase, Chinese WanFang Data, CBM, and CNKI were conducted for studies published up to June 2017. Randomized controlled trials (RCTs) of the treatment of DH with CSPS and potassium nitrate toothpaste were included. Quality assessment and data extraction were performed by two reviewers independently, and Meta-analysis was performed by using RevMan 5.3 software. RESULTS: Eight RCTs involving 411 patients were included. Experimental group comprised 203 and control group had 208 patients. The Meta-analysis indicated the superior effect of CSPS dentifrice on air blast sensitivity at 2, 4, 6, and 8 weeks of follow-up [SMD=-1.85, 95%CI (-2.89, â©-0.81), P=0.000 5, I²=93%], [SMD=-1.61, 95%CI (-1.96, -1.26), P<0.000 01, I²=49%], [SMD=-3.79, 95%CI (-7.18, -0.40), P=0.03, I²=98%], and [SMD=-2.13, 95%CI (-2.69, -1.58), P<0.000 01] , respectively. No significant effects were seen at 12 weeks [SMD=-0.63, 95%CI (-1.47, 0.20), P=0.14, I²=71%]. CSPS dentifrice showed a better desensitizing effect at 2, 4, 6, 8, and 12 weeks of follow-up on cold water sensitivity [SMD=-1.07, 95%CI (-1.48, -0.66), P<0.000 01, I²=69%], [SMD=â©-1.29, 95%CI (-1.81, -0.76), P<0.000 01, I²=64%], [SMD=-1.20, 95%CI (-1.57, -0.83), P<0.000 01, I²=86%], [SMD=-1.30, 95%CI (-2.51, -0.08), P=0.04, I²=82%], and [SMD=-0.79, 95%CI (-1.27, -0.31), P=0.001], respectively. No significant effects at 1 week of follow-up [SMD=0.00, 95%CI (-0.62, 0.62), P=1]. The favorable effect of CSPS dentifrice on tactile sensitivity was more obvious than the control group at 2, 4, and 8 weeks of follow-up [SMD=-1.31, 95%CI (-2.00, -0.62), P=0.000 2, I²=67%], [SMD=-1.37, 95%CI (-1.74, -0.99), P<0.000 01, I²=23%], and [SMD=-1.33, 95%CI (-1.82,-0.84), P<0.000 01], respectively. No significant effects at 1 week of follow-up [SMD=-0.32, 95%CI (-0.94, 0.31), P=0.32] were observed. CONCLUSIONS: Current evidence indicated that CSPS was more effective than potassium nitrate at reducing DH. The evidence generated by this review was based on a small number of individuals. High-quality and large sample size as well as ideally-designed clinical trials are required in the future before definitive recommendations can be made.